GtoPdb Ligand ID: 9554

Synonyms: compound 5 [PMID: 28151659]
Compound class: Synthetic organic
Comment: GSK2982772 is a first-in-class clinical candidate RIPK1 inhibitor, with anti-inflammatory potential [1]. X-ray structure of co-crystals shows GSK2982772 in a Type III-like kinase inhibitor position.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 100.21
Molecular weight 377.15
XLogP 2.98
No. Lipinski's rules broken 0
Canonical SMILES O=C(c1n[nH]c(n1)Cc1ccccc1)NC1COc2c(N(C1=O)C)cccc2
Isomeric SMILES O=C(c1n[nH]c(n1)Cc1ccccc1)N[C@H]1COc2c(N(C1=O)C)cccc2
InChI InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1
No information available.
Summary of Clinical Use
GSK2982772 is in Phase 2 clinical trials in psoriasis (NCT02776033), rheumatoid arthritis (NCT02858492), and ulcerative colitis (NCT02903966).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02776033 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis Phase 2 Interventional GlaxoSmithKline
NCT02858492 Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Phase 2 Interventional GlaxoSmithKline
NCT02903966 GSK2982772 Study in Subjects With Ulcerative Colitis Phase 2 Interventional GlaxoSmithKline